Clinical Trials Directory

This study looks at different treatments for early breast cancer (DCIS). It has four parts: - Screening: Doctors do tests to see if you can join. - Treatment: You’re randomly placed in a group to get either standard medicine or a new treatment. - Surgery Check: After 3 months, doctors decide if surgery is needed. - Follow-Up: You’ll get check-ups for up to 5 years, and yearly follow-ups for 10 years. Treatments may include pills, hormone therapy, or small pellets under the skin. You’ll also have tests like MRIs, mammograms, and blood samples.

We are doing this study to find out if the experimental combination of the drugs finalimab and cemiplimab (the study drugs) is a safe and effective option for people with high-risk melanoma. We want to see how well the study drugs work compared to treatment with pembrolizumab.

We are doing this study to learn more about the long-term effectiveness of an approved medicine that is prescribed for the treatment of EoE. We want to know how will dupilumab (Dupixent®) works over time when EoE patients and their doctors choose it as therapy. Dupilumab was approved by the FDA in May 2022 to treat EoE and was the first drug approved for this purpose.

If you decide to join this study, doctors will first check your medical history and the medicines you are taking to see if you can be part of it. If you qualify, you will have several tests, including: - A heart scan (CT or MRI) - An ultrasound of your heart - A full check-up, including your heart and brain if you had a stroke before - Blood tests to check things like salt levels, kidney and liver health, and heart function - A heart test called an ECG - A walking test to see how far you can walk in 6 minutes - A survey called the Kansas City Cardiomyopathy Questionnaire to learn how you feel Some visits may take a long time, up to 8 hours.

We are doing this study to find out if an experimental study drug called RP1 (the study drug) is a safe and effective option for people who have advanced melanoma. We want to know how the study drug works when it is combined with a cancer drug called nivolumab in comparison to several other standard treatments for advanced melanoma (nivolumab + relatlimab OR nivolumab alone OR pembrolizumab alone).

We are doing this study to find out if an experimental drug called RP2 (the study drug) is a safe and effective option for people who have uveal melanoma (melanoma in the eye). We want to know how well the study drug works when it is combined with a drug called nivolumab, and we will compare its outcomes to treatment with the drug combination of nivolumab + ipilimumab.

We are doing this study to find out if a drug called rosuvastatin (an FDA-approved medication for lowering cholesterol) can help reduce symptoms and extend the life expectancy of people with liver cirrhosis. Although rosuvastatin is an approved and commonly prescribed drug, it is not approved for the treatment of cirrhosis.